BLA 103836 · Horizon Therapeutics Ireland Dac
Actimmune
Interferon Gamma-1b · Single-Use · Interferon gamma
NovelOrphanLast checked: Nov 20, 2026Latest source record: Aug 27, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Feb 25, 1999
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
157
30 Phase 3, 19 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Interferon Gamma-1b" as an intervention, any sponsor and status, largest first.
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TBPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06568484 · 2,530 participants (planned) · Start May 8, 2026 · Primary completion Jul 2027
Drug: Bedaquiline; Levofloxacin · For: Tuberculosis, Latent
Sites: Ulaanbaatar, Mongolia; Lima, Peru; Mbeya, Tanzania · 8 sites in all
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06381661 · 2,000 participants (planned) · Start Jul 9, 2026 · Primary completion Aug 9, 2028
Drug: Tocilizumab; Baricitinib and 13 more · For: Sepsis
Sites: Dijon, France; Étampes, France; Garches, France · 19 sites in all
- Treatment of CIK for Patients With Refractory Non-Hodgkin LymphomaPivotal-lookingNot yet recruiting
The First People's Hospital of ChangzhouAcademic, hospital or other
NCT02497898 · 1,000 participants (planned) · Start Jul 2015 · Primary completion Jul 2038
Drug: Cytokine-induced killer cells (CIK) · For: Lymphoma, Non-Hodgkin
- QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.Pivotal-lookingCompleted
Hospital Universitari de BellvitgeAcademic, hospital or other
NCT01223534 · 871 participants · Start Jul 2010 · Primary completion Feb 2016
Drug: Preventive treatment with Isoniazid.; Preventive treatment with Isoniazid · For: Latent Tuberculosis Infection
Sites: L'Hospitalet de Llobregat, Barcelona, Spain
- Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal CancerPivotal-lookingTerminated
InterMuneIndustry
NCT00047632 · 847 participants · Start Oct 2001
Drug: Interferon gamma-1b · For: Ovarian Carcinoma; Peritoneal Carcinoma
Sites: Brisbane, California
- The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingTerminated
InterMuneIndustry
NCT00075998 · 826 participants · Start Dec 2003
Drug: Interferon gamma-1b ("Actimmune") · For: Idiopathic Pulmonary Fibrosis; Lung Disease; Pulmonary Fibrosis
Sites: Brisbane, California
- Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19Pivotal-lookingCompleted
SPP Pharmaclon Ltd.Industry
NCT05054114 · 630 participants · Start Dec 21, 2020 · Primary completion May 25, 2021
Drug: Interferon gamma human recombinant (IFN-G) · For: COVID-19 Respiratory Infection; Acute Respiratory Disease
Sites: Moscow, Russia
- Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or CirrhosisPivotal-lookingCompleted
InterMuneIndustry
NCT00043303 · 502 participants · Start Sep 2001
Drug: interferon gamma-1b · For: Liver Fibrosis; Cirrhosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Actimmune (Interferon Gamma-1b,Recomb.)
2024 spending
$27.6M
Beneficiaries
47
433 claims
Per beneficiary
$588,093
$10,983.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,353,185 |
| 2021 | $25,309,639 |
| 2022 | $27,310,873 |
| 2023 | $26,300,697 |
| 2024 | $27,640,388 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.
du Bois RM, Albera C, Bradford WZ, et al. · Eur Respir J 2014 · Clinical Trial, Phase III, Randomized Controlled Trial
- Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis.
Richeldi L · Eur Respir Rev 2012 · Systematic Review
- A critical assessment of treatment options for idiopathic pulmonary fibrosis.
Shah NR, Noble P, Jackson RM, et al. · Sarcoidosis Vasc Diffuse Lung Dis 2005 · Consensus Statement, Research Support, Non-U.S. Gov't
- Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease.
Todd PA, Goa KL · Drugs 1992 · Clinical Trial, Multicenter Study
- Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial.
Roquilly A, Francois B, Huet O, et al. · Intensive Care Med 2023 · Randomized Controlled Trial, Multicenter Study
- Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia.
Lynch DR, Hauser L, McCormick A, et al. · Ann Clin Transl Neurol 2019 · Multicenter Study, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.